134 related articles for article (PubMed ID: 23011763)
1. Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy.
Bišof V; Jakovčević A; Seiwerth S; Rakušić Z; Gašparov S
J Cancer Res Clin Oncol; 2013 Feb; 139(2):187-94. PubMed ID: 23011763
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
4. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
5. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.
Mehra R; Zhu F; Yang DH; Cai KQ; Weaver J; Singh MK; Nikonova AS; Golemis EA; Flieder DB; Cooper HS; Lango M; Ridge JA; Burtness B
Clin Cancer Res; 2013 Dec; 19(23):6633-43. PubMed ID: 24088734
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.
Patel MR; Zhao N; Ang MK; Stadler ME; Fritchie K; Weissler MC; Zanation AM; Harris SL; Funkhouser WK; Olshan AF; Shores CG; Hayes DN
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):587-95. PubMed ID: 23846458
[TBL] [Abstract][Full Text] [Related]
7. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
Hao D; Lau HY; Eliasziw M; Box A; Diaz R; Klimowicz AC; Shin B; Lees-Miller SP; Magliocco AM
Head Neck; 2012 Jun; 34(6):785-91. PubMed ID: 22127805
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.
Chen WH; Xin PL; Pan QX; Chen YY; Wang CR; Zhang ZS; Chen YF; Zhang CY; Cai WJ
PLoS One; 2014; 9(9):e106600. PubMed ID: 25191856
[TBL] [Abstract][Full Text] [Related]
9. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
[TBL] [Abstract][Full Text] [Related]
10. DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors.
Lima LM; de Souza LR; da Silva TF; Pereira CS; Guimarães AL; de Paula AM; de Andrade Carvalho H
Histopathology; 2012 Feb; 60(3):489-96. PubMed ID: 22176134
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.
Jun HJ; Ahn MJ; Kim HS; Yi SY; Han J; Lee SK; Ahn YC; Jeong HS; Son YI; Baek JH; Park K
Br J Cancer; 2008 Jul; 99(1):167-72. PubMed ID: 18594541
[TBL] [Abstract][Full Text] [Related]
12. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
[TBL] [Abstract][Full Text] [Related]
13. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
[TBL] [Abstract][Full Text] [Related]
14. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
15. Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer.
Johung K; Rewari A; Wu H; Judson B; Contessa JN; Haffty BG; Decker RH
Head Neck; 2013 Jun; 35(6):852-7. PubMed ID: 22740347
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer.
An HJ; Jo H; Jung CK; Kang JH; Kim MS; Sun DI; Cho KJ; Cho JH; Won HS; Sun S; Ko YH
Pathol Res Pract; 2017 Aug; 213(8):949-955. PubMed ID: 28645807
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy.
Sun JM; Sung JY; Park SH; Kwon GY; Jeong BC; Seo SI; Jeon SS; Lee HM; Jo J; Choi HY; Lim HY
BMC Cancer; 2012 May; 12():187. PubMed ID: 22616552
[TBL] [Abstract][Full Text] [Related]
18. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
Gao Y; Liu D
Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
[TBL] [Abstract][Full Text] [Related]
19. ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.
Prochnow S; Wilczak W; Bosch V; Clauditz TS; Muenscher A
Clin Oral Investig; 2019 Aug; 23(8):3319-3329. PubMed ID: 30498981
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma.
Hirakawa H; Ikegami T; Azechi S; Agena S; Uezato J; Kinjyo H; Yamashita Y; Tanaka K; Kondo S; Maeda H; Suzuki M; Gahana A
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):601-610. PubMed ID: 31749055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
